BRIEF published on 10/15/2024 at 07:35, 1 month 6 days ago Conclusion du recrutement pour l'essai clinique de MaaT Pharma Essai Clinique MaaT Pharma MaaT013 Avis DSMB Traitement AGvH
BRIEF published on 10/15/2024 at 07:35, 1 month 6 days ago MaaT Pharma Clinical Trial Recruitment Concluded Clinical Trial MaaT Pharma MaaT013 DSMB Notice AGvH Treatment
PRESS RELEASE published on 10/15/2024 at 07:30, 1 month 6 days ago Informations privilégiées / Autres communiqués MaaT Pharma annonce la fin du recrutement de son essai de Phase 3 ARES pour MaaT013 dans le traitement de la maladie aiguë du greffon contre l'hôte. Premiers résultats attendus en janvier 2025 MaaT Pharma MaaT013 Phase 3 ARES Maladie Aiguë Greffon Contre L'hôte
PRESS RELEASE published on 10/15/2024 at 07:30, 1 month 6 days ago Inside Information / Other news releases MaaT Pharma completes recruitment of its ARES Phase 3 Trial for MaaT013, a treatment for Acute Graft-versus-Host Disease, with topline results expected in January 2025 Clinical Trial MaaT Pharma MaaT013 ARES Phase 3 Trial Acute Graft-versus-Host Disease
BRIEF published on 09/04/2024 at 07:35, 2 months 17 days ago MaaT Pharma annonce sa participation à des conférences investisseurs et médicales en septembre Investisseurs Conférence Médicale Thérapies MET Transplantation Cellulaire Cancers
BRIEF published on 09/04/2024 at 07:35, 2 months 17 days ago MaaT Pharma Announces Participation in Investor and Medical Conferences in September Investors Cancers Medical Conference MET Therapies Cell Transplantation
PRESS RELEASE published on 09/04/2024 at 07:30, 2 months 17 days ago Informations privilégiées / Autres communiqués MaaT Pharma annonce sa participation aux conférences investisseurs et médicales en septembre, avec des présentations lors du Congrès annuel de la Society of Hematologic Oncology à Houston et à d'autres événements internationaux Conférences Investisseurs Microbiote MaaT Pharma Cancers
BRIEF published on 05/15/2024 at 07:35, 6 months 6 days ago MaaT Pharma clôture avec succès une levée de fonds de 19,2 millions d'euros Investissement Biotechnologie Essais Cliniques Levée De Fonds MaaT Pharma
BRIEF published on 05/15/2024 at 07:35, 6 months 6 days ago MaaT Pharma successfully completes a fundraising of 19.2 million euros Biotechnology Fundraising Investment MaaT Pharma Clinical Tests
Published on 11/21/2024 at 09:00, 54 minutes ago ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 9 hours 19 minutes ago Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 9 hours 29 minutes ago Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 00:00, 9 hours 54 minutes ago Swiss Mining Institute Conference Presentation
Published on 11/20/2024 at 23:00, 10 hours 54 minutes ago Rektron Group Inc. Announces Appointment of a New Director and Provides Corporate Updates
Published on 11/21/2024 at 09:41, 13 minutes ago Original-Research: 2G Energy AG (von First Berlin Equity Research GmbH): Buy
Published on 11/21/2024 at 08:59, 54 minutes ago Black Friday Savings: Kling AI Offers 50% Off and Free Feature Upgrades
Published on 11/21/2024 at 08:59, 54 minutes ago Économies Black Friday : Kling AI propose 50 % de réduction et des mises à niveau gratuites des fonctionnalités
Published on 11/21/2024 at 08:15, 1 hour 39 minutes ago EBIT increases to EUR 55.6 million. Equity (net asset value) increases by EUR 49.3 million to EUR 300.3 million, which corresponds to 70.14 euros per share. The equity ratio rises to 94.85%.
Published on 11/21/2024 at 06:58, 2 hours 56 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 2 hours 56 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 2 hours 56 minutes ago Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 13 hours 47 minutes ago Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 14 hours 34 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
